Drug Middlemen Aim to Avoid New Rules With Voluntary Changes

Pharmacy middlemen, also known as pharmacy benefit managers (PBMs), are working on a voluntary proposal to modify their business practices. This comes as the Trump administration considers new regulations targeting the PBM industry. PBMs act as intermediaries between drug manufacturers, pharmacies, and health plans, negotiating drug prices and rebates. However, they have faced criticism for their opaque pricing practices and for potentially contributing to high drug costs. The proposed voluntary changes aim to preempt potential government intervention. The details of the proposal are still under discussion, but it is expected to address issues such as transparency, rebate sharing, and the use of so-called "gag clauses" that restrict pharmacists from informing patients about lower-cost options. This move by the PBM industry reflects the growing scrutiny it faces from policymakers and the public over its role in the complex pharmaceutical supply chain. The voluntary changes, if implemented, could shape the regulatory landscape and impact the way PBMs operate in the future.